Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to an analyst’s considerable price target raise. Sarepta’s gain trounced that of the S&P 500 index, which bumped almost 0.3% higher on the day.
JPMorgan Chase gets more bullish on Sarepta
Before market open, JPMorgan Chase prognosticator Anupam Rama reset his price target on Sarepta to $177 per share. That’s well above his previous level of $112. Not surprisingly, he maintained his overweight (buy, in other words) recommendation on the veteran biotech company.
In his research note detailing the change, Rama wrote of the opportunity presented by the treatment of Duchenne muscular dystrophy (DMD). Sarepta has won approval for several medications for the disorder and has more currently in development.
The analyst waxed bullish about one of these drugs in particular, Elevidys. Some investors have been skittish about the company because the treatment’s Food and Drug Administration (FDA) approval in 2023 covered a narrower patient population than Sarepta was hoping for. Compounding that, recent clinical trial results for the drug were disappointing. Yet Rama feels that there is a chance that the scope of the approval will widen.
Elevated expectations for Elevidys
Much hinges on the future of Elevidys, as that less-than-inspiring performance led to a big Sarepta sell-off on the market. Since then, however, the stock has been inching up gradually; like Rama, we can expect that to accelerate if better regulatory news comes down the pipe for the DMD treatment.
Should you invest $1,000 in Sarepta Therapeutics right now?
Before you buy stock in Sarepta Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sarepta Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of January 22, 2024
JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy.
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today was originally published by The Motley Fool